Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Jones

Showing results (361-370 of 463) with videos related to

Pageof 47
Sort By:
Diabetes, Obesity & Metabolism|October 18, 2014
Is insulin the most effective injectable antihyperglycaemic therapy?J B Buse, A Peters, D Russell-Jones, et al.
Clinical Endocrinology|April 21, 1999
Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatmentP V Carroll, M Umpleby, E L Alexander, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
Advances in Therapy|August 25, 2011
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UKStephen C L Gough, Cristóbal Belda-Iniesta, Christopher Poole, et al.
Diabetologia|August 19, 2009
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialD Russell-Jones, A Vaag, O Schmitz, et al.
Biochimica Et Biophysica Acta|April 29, 2000
Functional expression in Pichia pastoris of human and rat intrinsic factorJ Wen, M B Kinnear, M A Richardson, et al.
Clinical Medicine (London, England)|July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UKHarry Knights, Nikhil Mayor, Kristina Millar, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2012
Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndromeM Denise Robertson, John W Wright, Emmanuelle Loizon, et al.
Clinical and Experimental Dermatology|June 4, 2010
Aggressive epidermotropic cutaneous CD8+ (Berti's) lymphomaN K Webber, C Harwood, P Goldsmith, et al.
Diabetes|September 1, 1997
rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDMP V Carroll, M Umpleby, G S Ward, et al.
Pageof 47

Showing results (361-370 of 463) with videos related to

Sort By:
Pageof 47
Diabetes, Obesity & Metabolism|October 18, 2014
Is insulin the most effective injectable antihyperglycaemic therapy?J B Buse, A Peters, D Russell-Jones, et al.
Clinical Endocrinology|April 21, 1999
Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatmentP V Carroll, M Umpleby, E L Alexander, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
Advances in Therapy|August 25, 2011
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UKStephen C L Gough, Cristóbal Belda-Iniesta, Christopher Poole, et al.
Diabetologia|August 19, 2009
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialD Russell-Jones, A Vaag, O Schmitz, et al.
Biochimica Et Biophysica Acta|April 29, 2000
Functional expression in Pichia pastoris of human and rat intrinsic factorJ Wen, M B Kinnear, M A Richardson, et al.
Clinical Medicine (London, England)|July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UKHarry Knights, Nikhil Mayor, Kristina Millar, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2012
Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndromeM Denise Robertson, John W Wright, Emmanuelle Loizon, et al.
Clinical and Experimental Dermatology|June 4, 2010
Aggressive epidermotropic cutaneous CD8+ (Berti's) lymphomaN K Webber, C Harwood, P Goldsmith, et al.
Diabetes|September 1, 1997
rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDMP V Carroll, M Umpleby, G S Ward, et al.
Pageof 47